Orphan Drugs Industry Advisory & Intelligence
Skip to content
Home
About us
ODI Advisory
Press, Articles & News
References
←
Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 1 – The Novartis case
Just started a vertical consulting practice focused on Inborn Errors of Metabolism (IEMs)
→
Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 2 – The Pfizer case
Posted on
May 2, 2016
by
christian@orphandrugsindustry.com
Link to article
Share this:
Twitter
Facebook
LinkedIn
Print
Reddit
Tumblr
Email
Pinterest
Pocket
This entry was posted in
Pulse
and tagged
Big pharma
,
Orphan drugs
,
Rare diseases
. Bookmark the
permalink
.
←
Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 1 – The Novartis case
Just started a vertical consulting practice focused on Inborn Errors of Metabolism (IEMs)
→
Search for:
Archives
May 2019
May 2016
April 2016
Meta
Register
Log in
Click to contact us
Visitors
4,046 hits
Send to Email Address
Your Name
Your Email Address
Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here:
Our Cookie Policy
